OncLive TV

Ashley Sumrall, MD, FACP, FASCO, discusses CAR T-cell therapies and BTK inhibitors in primary central nervous system lymphoma and the role they play.

Bradley Monk, MD, FACOG, FACS, discusses the relevance of FRα, HER2, and PD-L1 expression in influencing decision-making in recurrent ovarian cancer.

Mina M. Fam, MD, and Bradley McGregor, MD, discuss the treatment landscape of testicular cancer during Testicular Cancer Awareness Month.

Timothy N. Clinton, MD, discusses initiatives to improve outcomes for female patients with bladder cancer.

Vinayak Venkataraman, MD, discusses how certain biological requirements for emerging cellular therapies could exacerbate racial disparities in sarcoma.

Oncology experts share perspectives and suggest advice for reducing burnout related to conference attendance and taking personal time away from the clinic.

Colton Jones, MD, discusses real-world data comparing GLP-1 receptor agonists and aspirin for the primary prevention of colorectal cancer.

Timothy N. Clinton, MD, discusses biologic and anatomical differences underlying sex and gender disparities in bladder cancer incidence.

Top experts discuss the most important takeaways and data to come out of this year’s SGO Annual Meeting on Women’s Cancer.

Sara M. Tolaney, MD, MPH, discusses how the shifting understanding of HER2 expression in breast cancer may affect the management of this disease.

Timothy N. Clinton, MD, discusses differences between genders in terms of bladder cancer presentation.

Adanma Ayanambakkam, MD, MS, discusses the safety profile of darlifarnib plus cabozantinib in ccRCC.

Jonathan Wennan Lee, MD, MSc; and Ashish Saxena, MD, PhD, discuss the future for evaluating PD-L1 expression as a biomarker in EGFR-mutated NSCLC.

Brian M. Wolpin, MD, MPH, discusses phase 1/2 data showing high activity with daraxonrasib in first-line metastatic pancreatic ductal adenocarcinoma.

Sara M. Tolaney, MD, MPH, discusses how the early-stage HER2-positive breast cancer treatment paradigm is evolving with the emergence of new phase 3 data.

Rena D. Callahan, MD, discusses the clinical utility and shifting paradigms of oral SERDs for patients with ER-positive advanced breast cancer.

Sara M. Tolaney, MD, MPH, discusses how therapeutic strategies are evolving within the HER2-positive breast cancer treatment paradigm.

Rena D. Callahan, MD, notes the implications of adding camizestrant to an aromatase inhibitor in ER-positive breast cancer with an emergent ESR1 mutation.

Jesús Berdeja, MD, discusses the optimal timing of CAR T-cell therapy referral for patients with multiple myeloma.

Adanma Ayanambakkam, MD, MS, discusses efficacy data from the phase 1a/1b FIT-001 trial.

Adanma Ayanambakkam, MD, MS, discusses the mechanism of action of darlifarnib in ccRCC.

Jonathan Wennan Lee, MD, MSc; and Ashish Saxena, MD, PhD, note data from a study of PD-L1 expression as a marker of response to TKIs in EGFR-mutated NSCLC.

Jonathan Wennan Lee, MD, MSc; and Ashish Saxena, MD, PhD, discuss the role for PD-L1 expression as a biomarker for treatment response in EGFR-mutant NSCLC.

Rena D. Callahan, MD, discusses the implications of the NATALEE trial of adjuvant ribociclib plus endocrine therapy in HR-positive early breast cancer.

Vinayak Venkataraman, MD, spotlights a focus-group study identifying mobility, autonomy, and supportive care gaps in AYA patients with sarcoma.

Taigo Kato, MD, PhD, discusses the use of ctDNA-guided therapy in patients with RCC.

Peter C. Enzinger, MD, discusses the significance of Claudin 18.2 and HER2 as actionable biomarkers in gastroesophageal cancer.

Fangdi Sun, MD, discusses how biomarker testing can help navigate the complexity of treatment decision-making across the spectrum of head and neck cancers.

Taigo Kato, MD, PhD, discusses future directions of MONSTAR-SCREEN-3 and how data from the study can be applied to clinical practice.

Taigo Kato, MD, PhD, discusses the background of the MONSTAR-SCREEN-3 in resectable RCC and the key findings from the study.